- Home
- ORMP vs VRXA Comparison
ORMP vs VRXA Comparison
Compare ORMP & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORMP | VRXA |
|---|---|---|
| Founded | 2002 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.6M | 161.2M |
| IPO Year | 2010 | 2025 |
Fundamental Metrics
Financial Performance| Metric | ORMP | VRXA |
|---|---|---|
| Price | $3.85 | $1.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 107.6K | ★ 150.8K |
| Earning Date | 11-12-2026 | N/A |
| Dividend Yield | ★ 6.20% | N/A |
| EPS Growth | ★ 412.50 | N/A |
| EPS | ★ 3.17 | N/A |
| Revenue | ★ $2,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.47 | ★ N/A |
| Revenue Growth | ★ 49.25 | N/A |
| 52 Week Low | $2.25 | $0.90 |
| 52 Week High | $5.47 | $4.50 |
Technical Indicators
Market Signals| Indicator | ORMP | VRXA |
|---|---|---|
| Relative Strength Index (RSI) | 38.22 | 49.24 |
| Support Level | $3.55 | $0.96 |
| Resistance Level | $3.96 | $1.25 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 6.38 | 46.53 |
Price Performance
Historical ComparisonAbout ORMP Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
About VRXA Veraxa Biotech AG Ordinary Shares
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.